Related Experiment Video
Updated: Sep 27, 2026

Assessment of Sensorimotor Function in Mouse Models of Parkinson's Disease
Published on: June 17, 2013
Mice lacking Faim2 show increased cell death in the MPTP mouse model of Parkinson disease
Daniel Komnig1, Jörg B Schulz1,2, Arno Reich1
1Department of Neurology, RWTH University Aachen, Aachen, Germany.
Abstract:
The death receptor Fas/CD95 mediates apoptotic cell death in response to external stimuli. In neurons, Fas-induced apoptosis is prevented by Fas-apoptotic inhibitory molecule 2 (Faim2). Mice lacking Faim2 showed increased neurodegeneration in animal models of stroke and bacterial meningitis. We therefore tested the relevance of Faim2 in a classical animal model of Parkinson disease and determined the toxicity of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) in Faim2-deficient mice. Without MPTP treatment, there was no difference in the dopaminergic system between Faim2-deficient mice and control mice. MPTP was applied i.p. in doses of 30 mg per kg on five consecutive days. Fourteen days after the last MPTP injection, the number of dopaminergic neurons in the lateral substantia nigra, assayed by stereological counting, was reduced by 39% in control mice and 53% in Faim2-deficient mice. The density of dopaminergic fibers in the dorsal striatum was reduced by 36% in control mice and 69% in Faim2-deficient mice, in the ventral striatum 44% in control mice and 76% in Faim2-deficient mice. Fiber density recovered at 90 days after MPTP with similar density in both groups. Striatal catecholamine levels were reduced by 81-84% in both groups and recovered at 90 days. Faim2 expression was documented in mouse midbrain using quantitative reverse transcription-PCR (qRT-PCR) and found decreased after MPTP administration. Taken together, our findings demonstrate increased degeneration of dopaminergic neurons with Faim2 deficiency, indicating that Fas-induced apoptosis contributes to cell death in the MPTP mouse model. Along with the decreased expression of Faim2 after MPTP, this finding indicates that boosting Faim2 function might represent a therapeutic strategy for Parkinson disease.
Insights
Fas-apoptotic inhibitory molecule 2 (Faim2) deficiency exacerbates neurodegeneration in a Parkinson disease model. Boosting Faim2 may offer a therapeutic strategy for Parkinson disease.
Area of Science:
- Neuroscience
- Molecular Biology
- Neurodegeneration
Background:
- The death receptor Fas/CD95 mediates apoptosis, a process inhibited in neurons by Fas-apoptotic inhibitory molecule 2 (Faim2).
- Faim2 deficiency leads to increased neurodegeneration in models of stroke and bacterial meningitis.
- The role of Faim2 in Parkinson disease pathogenesis remains unclear.
Purpose of the Study:
- To investigate the role of Faim2 in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) mouse model of Parkinson disease.
- To determine the impact of Faim2 deficiency on dopaminergic neuron toxicity induced by MPTP.
Main Methods:
- MPTP was administered to Faim2-deficient and control mice.
- Stereological counting assessed dopaminergic neuron numbers in the substantia nigra.
- Dopaminergic fiber density in the striatum was quantified.
- Striatal catecholamine levels were measured.
- Faim2 expression in the midbrain was analyzed using qRT-PCR.
Main Results:
- Faim2-deficient mice exhibited significantly greater loss of dopaminergic neurons and striatal fibers after MPTP treatment compared to controls.
- While initial catecholamine levels were similarly reduced in both groups, fiber density recovered by 90 days post-MPTP.
- MPTP administration led to decreased Faim2 expression in the mouse midbrain.
Conclusions:
- Faim2 deficiency increases dopaminergic neuron degeneration in the MPTP model, suggesting Fas-induced apoptosis contributes to Parkinson disease pathology.
- Reduced Faim2 expression following MPTP insult highlights its potential as a therapeutic target.
- Enhancing Faim2 function could be a novel strategy for treating Parkinson disease.

